Display options
Cite
Beyazyüz M, Albayrak Y, Beyazyüz E, et al. Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia. Neuropsychiatr Dis Treat. 2014;10:687-93doi: 10.2147/NDT.S61406.
Beyazyüz, M., Albayrak, Y., Beyazyüz, E., Unsal, C., & Göka, E. (2014). Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia. Neuropsychiatric disease and treatment, 10687-93. https://doi.org/10.2147/NDT.S61406
Beyazyüz, Murat, et al. "Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia." Neuropsychiatric disease and treatment vol. 10 (2014): 687-93. doi: https://doi.org/10.2147/NDT.S61406
Beyazyüz M, Albayrak Y, Beyazyüz E, Unsal C, Göka E. Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia. Neuropsychiatr Dis Treat. 2014 Apr 29;10:687-93. doi: 10.2147/NDT.S61406. eCollection 2014. PMID: 24812513; PMCID: PMC4011925.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2014 Apr 29;10:687-93. doi: 10.2147/NDT.S61406. eCollection 2014.

Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia.

Neuropsychiatric disease and treatment

Murat Beyazyüz, Yakup Albayrak, Elmas Beyazyüz, Cüneyt Unsal, Erol Göka

Affiliations

  1. Department of Psychiatry, Gölba?? Hasvak State Hospital, Ankara, Turkey.
  2. Department of Psychiatry, School of Medicine, Nam?k Kemal University, Tekirda?, Turkey.
  3. Department of Psychiatry, Ankara Numune Education and Research Hospital, Ankara, Turkey.

PMID: 24812513 PMCID: PMC4011925 DOI: 10.2147/NDT.S61406

Abstract

BACKGROUND: Many studies have investigated the relationship between blood levels of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEA-S), cortisol, progesterone, and testosterone and the onset, prognosis, symptom severity, and treatment response of schizophrenia. In the present study, we assessed potential differences in blood levels of neurosteroids between drug-naïve first-episode patients with schizophrenia (FES), and drug-free patients with schizophrenia who were not in the first episode but were in a phase of acute exacerbation (DFP).

MATERIALS AND METHODS: The present study included 32 male FES, 28 male DFP, and 24 male healthy controls (HC). Groups were compared in terms of blood levels of adrenocorticotropic hormone (ACTH), cortisol, testosterone, progesterone, and DHEA-S.

RESULTS: Blood levels of ACTH, cortisol, testosterone, and progesterone were similar among the groups. The mean value of serum DHEA-S was significantly different among the groups (P<0.001). The value of serum DHEA-S was higher in the FES group than in the DFP and HC groups (both P<0.001). The mean values of serum DHEA-S in the HC and DFP groups were found to be similar (P=0.33).

CONCLUSION: We suggest that higher values of DHEA-S in the FES group compared with both the DFP and HC groups indicate that this neurosteroid response is unique to first-episode schizophrenia patients. Further studies are needed to investigate the difference in blood levels of neurosteroids in different groups in terms of age of diagnosis.

Keywords: effect; neurosteroid; psychosis

References

  1. Biol Psychiatry. 1983 May;18(5):583-90 - PubMed
  2. Biol Psychiatry. 1979 Apr;14(2):395-404 - PubMed
  3. Neuropsychopharmacology. 2001 Mar;24(3):278-90 - PubMed
  4. Psychol Med. 2000 Sep;30(5):1227-31 - PubMed
  5. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4704-7 - PubMed
  6. Biol Psychiatry. 2000 Dec 15;48(12):1121-32 - PubMed
  7. Psychiatry Clin Neurosci. 2011 Oct;65(6):584-91 - PubMed
  8. Brain Res Brain Res Rev. 2001 Nov;37(1-3):59-67 - PubMed
  9. Ann N Y Acad Sci. 2004 Dec;1032:291-4 - PubMed
  10. Front Neuroendocrinol. 2009 Jan;30(1):65-91 - PubMed
  11. Psychiatr Clin North Am. 1998 Jun;21(2):413-34 - PubMed
  12. J Psychiatr Res. 2012 Nov;46(11):1421-6 - PubMed
  13. Med Princ Pract. 2007;16(2):137-41 - PubMed
  14. Psychoneuroendocrinology. 1994;19(4):373-85 - PubMed
  15. Neuroscience. 2001;102(2):427-32 - PubMed
  16. J Clin Endocrinol Metab. 1992 Oct;75(4):1002-4 - PubMed
  17. Biol Psychiatry. 2000 Oct 1;48(7):693-701 - PubMed
  18. CNS Neurosci Ther. 2010 Spring;16(1):32-44 - PubMed
  19. J Endocrinol Invest. 1998 Mar;21(3):148-53 - PubMed
  20. J Clin Endocrinol Metab. 1975 May;40(5):850-5 - PubMed
  21. Med Chem. 2013 Sep;9(6):763-73 - PubMed
  22. J Psychiatr Res. 2011 Oct;45(10):1358-65 - PubMed
  23. CNS Spectr. 2001 Jan;6(1):75-88 - PubMed
  24. Can J Psychiatry. 1997 Apr;42(3):255-64 - PubMed
  25. Eur Neuropsychopharmacol. 2004 Aug;14(4):267-73 - PubMed
  26. Eur Neuropsychopharmacol. 2009 Jul;19(7):499-503 - PubMed
  27. FASEB J. 1992 Mar;6(6):2311-22 - PubMed
  28. Schizophr Res. 1988 Nov-Dec;1(6):405-10 - PubMed
  29. Schizophr Res. 2002 Nov 1;58(1):69-74 - PubMed
  30. Front Cell Neurosci. 2013 Jun 26;7:95 - PubMed
  31. J Clin Endocrinol Metab. 1997 Jul;82(7):2363-7 - PubMed
  32. J Endocrinol. 1996 Sep;150 Suppl:S221-39 - PubMed
  33. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1852-7 - PubMed
  34. Brain Res Mol Brain Res. 2002 Jan 31;98(1-2):58-66 - PubMed
  35. Schizophr Res. 2004 Dec 1;71(2-3):427-34 - PubMed
  36. Psychol Rev. 1997 Oct;104(4):667-85 - PubMed
  37. Psychother Psychosom. 2002 Sep-Oct;71(5):298-303 - PubMed

Publication Types